logo

Relmada Therapeutics, Inc. (RLMD)



Trade RLMD now with
  Date
  Headline
8/9/2022 8:32:38 AM Relmada Therapeutics Receives FDA Fast Track Designation For REL-1017 As Monotherapy For Major Depressive Disorder
4/29/2022 8:32:51 AM Relmada Therapeutics Announces Publication Of REL-1017 Preclinical Data In Frontiers In Pharmacology
2/23/2022 7:29:03 AM Relmada Announces Top-Line Results Of REL-1017 Vs Ketamine For Abuse Potential; Stock Up
12/22/2021 9:15:03 AM Relmada Announces Publication Of REL-1017 Phase 2 Study Results In American Journal Of Psychiatry
12/8/2021 11:39:14 PM Relmada Therapeutics Prices Public Offering Of 8.82 Mln Shares At $17/Shr
10/4/2021 8:37:24 AM FDA Confirms Relmada Not Required To Conduct Two-Year Carcinogenicity Study
7/27/2021 7:42:43 AM Relmada Therapeutics Announces Top-Line Results Of Study Evaluating REL-1017 Vs Oxycodone For Abuse Potential
7/20/2021 8:17:01 AM Relmada Therapeutics Announces Acquisition Of Commercial Rights To Psilocybin And Derivates Program From Arbormentis
5/26/2021 8:29:51 AM Relmada Therapeutics To Present REL-1017 Clinical Data At 2021 ASCP Annual Meeting